A new transmucous-buccal formulation of acetaminophen for acute traumatic pain: A non-inferiority, randomized, double-blind, clinical trial

Pain Physician

Volumn 18, Issue 3, 2015, Pages 249-257

  Pickering, Gisele ^b,c   Moustafa, Fares ^a   Macian, Nicolas ^a   Schmidt, Jeannot ^a   Pereira, Bruno ^a   Dubray, Claude ^a,b,c  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Pain; Transmucosal delivery; Trauma

Indexed keywords

PARACETAMOL; PLACEBO; ANALGESIC AGENT; EMULSION;

ADULT; ANALGESIA; ARM PAIN; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; FEMALE; HUMAN; LEG PAIN; MALE; NUMERIC PAIN RATING SCALE; PAIN ASSESSMENT; PAIN INTENSITY; POSTTRAUMATIC PAIN; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TRANSMUCOUS BUCCAL FORMULATION; TREATMENT OUTCOME; ACUTE PAIN; BUCCAL DRUG ADMINISTRATION; COMPLICATION; DRUG DELIVERY SYSTEM; EMULSION; INJURY; LEG; MEDICINAL CHEMISTRY; MIDDLE AGED;

ACETAMINOPHEN; ACUTE PAIN; ADMINISTRATION, BUCCAL; ADULT; ANALGESICS, NON-NARCOTIC; CHEMISTRY, PHARMACEUTICAL; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; EMULSIONS; FEMALE; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; WOUNDS AND INJURIES;

EID: 84929459010     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987; 59:850-856.
2. Pickering G, Schneider E, Papet I, Pujos- Guillot E, Pereira B, Simen E, Dubray C, Schoeffler P. Acetaminophen metabolism after major surgery: A bigger challenge when aging. Clin Pharmacol Ther 2011; 90:707-711.
3. Nelson AE, Allen KD, Golightly YM, Goode AP, Jordan JM. A systematic review of recommendations and guidelines for the management of osteoarthritis: The Chronic Osteoarthritis Management Initiative of the U.S. Bone and Joint Initiative. Semin Arthritis Rheum 2014; 43:701-712.
4. Wise J. NICE keeps paracetamol in UK guidelines on osteoarthritis. BMJ 2014; 13:1545.
5. Albertson TE, Walker VM, Jr, Stebbins MR, Ashton EW, Owen KP, Sutter ME. A population study of the frequency of high-dose acetaminophen prescribing and dispensing. Ann Pharmacother 2010; 44:1191-1195.
6. www.fda.gov/Drugs/DrugSafety/ucm394916.htm consulted (27 July 2014)
7. Pinson GM, Beall JW, Kyle JA. A review of warfarin dosing with concurrent acetaminophen therapy. J Pharm Pract 2013; 26:518-521.
8. Pickering G, Macian N, Libert F, Perovitch P, Maury M, Dubray C. Buccal acetaminophen provides fast analgesia: Two randomized clinical trials in healthy volunteers. Drug Design, Development and Therapy 2014; 26:1621-1627.
9. Mao J. Current challenges in translational pain research. Trends Pharmacol Sci 2012; 33:568-573.
10. Mehlish DR. A single-tablet fixed-dose combination of racemic ibuprofen/ paracetamol in the management of moderate to severe postoperative dental pain in adult and adolescent patients: A multicenter, two-stage, randomized, double-blind, parallel-group, placebocontrolled, factorial study. Clinical Therapeutics 2010; 32:1034-1049.
11. Boureau F. Evaluation of ibuprofen vs paracetamol analgesic activity using a sore throat pain model. Clin Drug investigation 1999; 17:1-8.
12. Tzortzopoulou A, McNicol ED, Cepeda MS, Francia MB, Farhat T, Schumann R. Single dose intravenous propacetamol or intravenous paracetamol for postoperative pain. Cochrane Database Syst Rev 2011; 10:CD007126.
13. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement. JAMA 2006; 295:1152-1160.
14. Zhao L, Pickering G. Paracetamol metabolism and related genetic differences. Drug Metab Rev 2011; 43:41-52.
15. Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, Frigerio V, Ingham J, Loseth DB, Nordbrock E, Rhiner M. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: A controlled dose titration study. Pain 1999; 79:303-312.
16. Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: The challenge of its dosing. Crit Rev Oncol Hematol 2011; 80:460-465.
17. Gombert-Handoko KB. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. Clin Ther 2014; 14:387-387
18. Borland M, Milsom S, Esson A. Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: A randomized controlled trial. Emerg Med Australas 2011; 23:202-208.
19. Piguet V, Desmeules J, Dayer P. Lack of acetaminophen ceiling effect on RIII nociceptive flexion reflex. Eur J Clin Pharmacol 1998; 53:321-324.
20. Rumack B. Aspirin versus acetaminophen: A comparative view. Paediatrics 1978; 62:943-946.
21. Anderson B, Holford N, Woollard GA, Kanagasundaram S, Mahadevan M. Perioperative pharmacodynamics of acetaminophen analgesia in children. Anaesthesiology 1999; 90:411-421.
22. Holmer-Pettersson P, Owall A, Jakobsson J. Early bioavailability of paracetamol after oral or intravenous administration. Acta Anaesthesiol Scand 2004; 48:867-870.
23. Anderson B, Holford N. Rectal paracetamol dosing regimens: determination by computer simulation. Paediatr Anaesth 1997; 7:451-455.
24. Oscier M, Bosley B, Milner S. Paracetamol: A review of three routes of administration. Update in Anesthesia 2007; 23:112-114.
25. Hogestatt ED, Jonsson BA, Ermund A, Andersson DA, Bjork H, Alexander JP, Cravatt BF, Basbaum AI, Zygmunt PM. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 2005; 280:31405-31412.
26. Fischer V, West PR, Nelson SD, Harvison PJ, Mason RP. Formation of 4-aminophenoxyl free radical from the acetaminophen metabolite N-acetyl-pbenzoquinone imine. J Biol Chem 1985; 260:11446-11450.
27. Andersson DA, Gentry C, Alenmyr L, Killander D, Lewis SE, Andersson A, Bucher B, Galzi JL, Sterner O, Bevan S, Hogestatt ED, Zygmunt PM. TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Δ(9)-tetrahydrocannabiorcol. Nat Commun 2011; 2:551-553.
28. Pickering G, Loriot MA, Libert F, Eschalier A, Beaune P, Dubray C. Analgesic effect of acetaminophen in humans: First evidence of a central serotonergic mechanism. Clin Pharmacol Ther 2006; 79:371-378.
29. Pickering G, Esteve V, Loriot MA, Eschalier A, Dubray C. Acetaminophen reinforces descending inhibitory pain pathways. Clin Pharm Ther 2008; 84:47-50.
30. Pickering G, Moustafa F, Desbrandes S, Cardot JM, Roux D, Dubray C. Paracetamol and opioid pathways: A pilot randomised clinical trial. Fund Clin Pharmacol 2013; 27:339-345.
31. Pini LA, Sandrini M, Vitale G. The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Eur J Pharmacol 1996; 308:31-40.
32. Mallet C, Barriere DA, Ermund A, Jonsson BA, Eschalier A, Zygmunt PM, Hogestatt ED. TRPV(1) in brain is involved in acetaminophen-induced antinociception. PLoS One 2010; 5:12748-12751.
33. Andersson DA, Gentry C, Alenmyr L, Killander D, Lewis SE, Andersson A, Bucher B, Galzi JL, Sterner O, Bevan S, Hogestatt ED, Zygmunt PM. TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Δ(9)-tetrahydrocannabiorcol. Nat Commun 2011; 2:551-553.
34. Alloui A, Pelissier T, Dubray C, Lavarenne J, Eschalier A. Tropisetron inhibits the antinociceptive effect of intrathecally administered paracetamol and serotonin. Fundam Clin Pharmacol 1996; 10:406-407.
35. Kerckhove N, Mallet C, Francois A, Boudes M, Chemin J, Voets T, Bourinet E, Alloui A, Eschalier A. Ca(v)3.2 calcium channels: The key protagonist in the supraspinal effect of paracetamol. Pain 2014; 155:764-772.
36. Vondracek M, Xi Z, Larsson P, Baker V, Mace K, Pfeifer A, Tjalve H, Donato MT, Gomez-Lechon MJ, Grafstrom RC. Cytochrome P450 expression and related metabolism in human buccal mucosa. Carcinogenesis 2011; 22:481-488.
37. Sarikaya D, Chiba I, Bilgen C, Kamatakii T, Topcu Z. RT-PCR-based cytochrome P450 expression profile of oral tissue samples. J Clin Pharm Ther 2007; 32:445-448.
38. Campisi G, Paderni C, Saccone R, Di Fede O, Wolff A, Giannola LI. Human buccal mucosa as an innovative site of drug delivery. Curr Pharm Des 2010; 6:641-652.
39. Oliveira G, Beezer AE, Hadgraft J, Lane ME. Alcohol enhanced permeation in model membranes. Part I: thermodynamic and kinetic analyses of membrane permeation. Int J Pharm 2010; 393:61-67.
40. Dixit S1, Crain J, Poon WC, Finney JL, Soper AK. Molecular segregation observed in a concentrated alcohol-water solution. Nature 2002; 416:829-832.
41. Pradhan TL, Ghoshal P, Biswas R Excited state intramolecular charge transfer reaction in binary mixtures of water and tertiary butanol (TBA): Alcohol mole fraction dependence. Phys Chem A 2008; 112:915-924.
42. Mantle MD. NMR and MRI studies of drug delivery systems current opinion in colloid and interface. Science 2013; 18:214-227.
43. Pardridge WM Drug transport across the blood–brain barrier. Journal of Cerebral Blood Flow and Metabolism 2012; 32:1959-1972.
44. Slosky LM, Thompson BJ, Sanchez-Covarrubias L, Zhang Y, Laracuente ML, Vanderah TW, Ronaldson PT, Davis TP. Acetaminophen modulates P-glycoprotein functional expression at the bloodbgrain barrier by a constitutive androstane receptor-dependent mechanism. Mol Pharmacol 2013; 84:774-786.
45. Liu Q, Hou J, Chen X, Liu G, Zhang D, Sun H, Zhang J. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson’s disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models. PLoS One 2014; 9:e102442.